Your session is about to expire
← Back to Search
Virtual Care Transition for COPD (TELE-TOC Trial)
N/A
Waitlist Available
Led By Valerie G Press, MD, MPH
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 -days
Awards & highlights
No Placebo-Only Group
Summary
This trial will evaluate if virtual visits can improve care transitions for COPD patients, reducing hospital readmissions and medication safety events.
Who is the study for?
This trial is for adults aged 40 or older who have been hospitalized with a COPD exacerbation and are part of the COPD Hospital Readmission Reduction Program. It's designed to help those at high risk for readmission and medication issues.
What is being tested?
The study tests a telehealth intervention called TELE-TOC, which includes virtual visits and pharmacy-based in-home support after hospital discharge, aiming to improve medication use and health outcomes in COPD patients.
What are the potential side effects?
Since this trial focuses on education and telehealth services rather than medications, there are no direct side effects like you'd expect from drugs. However, technical issues or miscommunication could potentially occur.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 180 -days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 -days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Correct inhaler technique 30 days post discharge
Reach of the TELE-TOC intervention
Secondary study objectives
180 day revisits
30 day revisits
90 day revisits
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TELE-TOC plus Usual CareExperimental Treatment6 Interventions
Patients randomized to this arm will receive the TELE-TOC intervention as well as the standard COPD care via the institution's COPD readmission reduction program.
Group II: Usual CareActive Control4 Interventions
Patients randomized to this arm will receive standard COPD care via the institution's COPD readmission reduction program.
Find a Location
Who is running the clinical trial?
Society of Hospital MedicineOTHER
5 Previous Clinical Trials
23,954 Total Patients Enrolled
COPD FoundationOTHER
17 Previous Clinical Trials
238,110 Total Patients Enrolled
Washington University School of MedicineOTHER
1,997 Previous Clinical Trials
2,298,561 Total Patients Enrolled
Hospital Medicine Reengineering Network (HOMERuN)UNKNOWN
The American Telemedicine AssociationUNKNOWN
University of ChicagoLead Sponsor
1,058 Previous Clinical Trials
765,396 Total Patients Enrolled
Agency for Healthcare Research and Quality (AHRQ)FED
406 Previous Clinical Trials
6,757,011 Total Patients Enrolled
Valerie G Press, MD, MPHPrincipal InvestigatorUniversity of Chicago
3 Previous Clinical Trials
333 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am younger than 40 years old.I am over 40 and hospitalized for a COPD flare-up.I am currently in the intensive care unit.
Research Study Groups:
This trial has the following groups:- Group 1: TELE-TOC plus Usual Care
- Group 2: Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.